Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600-mutant pediatric low-grade glioma (pLGG)

Authors
Category Primary study
ConferenceJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: fcf3b8c941d5347e03f6383706593e38745aad94
First added on: Feb 14, 2025